Illumina, Inc.

In 2023, a group of visionary scientists and investors recognized that drug discovery remained an expensive, time-consuming process with high failure rates. Despite advances in AI, the pharmaceutical industry was still struggling to translate computational insights into viable medicines. This realization sparked the creation of Xaira Therapeutics - co-founded and incubated by ARCH Venture Partners and Foresite Labs - to build an integrated biotechnology company that would truly harness the transformative power of artificial intelligence for drug discovery. Built on the groundbreaking protein design work of Nobel Laureate Dr. David Baker and his team at the University of Washington's Institute for Protein Design, Xaira brings together advanced AI research, expansive data generation, and robust therapeutic product development. The company emerged from stealth mode in 2024 with over $1 billion in funding, ready to revolutionize how we treat disease by making predictions about the right biology to target, the best therapeutics to modulate those targets, and the patients who will benefit most. With offices in South San Francisco, Seattle, and London, Xaira is shifting drug discovery from an empirical science to a precise engineering discipline.

Invivoscribe is a global leader in precision oncology diagnostics, dedicated to improving lives with standardized molecular testing solutions. For over 30 years, the company has pioneered the international standardization of molecular and flow cytometry testing, expanding access to advanced cancer therapies worldwide. Invivoscribe develops and manufactures a comprehensive portfolio of molecular assays, reagents, controls, and bioinformatics tools under ISO 13485 design control, supporting more than 700 clinical laboratories in over 160 countries. The company's Streamlined CDx (companion diagnostic) model accelerates the development of novel therapeutics, enabling personalized approaches to patient care. Invivoscribe's products consistently surpass industry and regulatory standards, playing a crucial role in identifying, stratifying, and monitoring hematologic cancers. Through its subsidiary, the Laboratory for Personalized Molecular Medicine (LabPMM), Invivoscribe offers extensive clinical diagnostic and biopharma services, providing globally standardized flow cytometry and molecular testing services for pharmaceutical and healthcare organizations across the U.S., Europe, and Asia.

CorDx is a multinational biotechnology company specialising in rapid testing and point-of-care medical device solutions for infectious diseases and other health needs. Its proprietary diagnostic products - spanning infectious disease detection (including COVID-19), pregnancy testing, drug screening, and biomarker detection - hold CE Marks and approvals from regulatory bodies including the FDA, serving both healthcare providers and consumers. The company employs more than 2,100 people and maintains manufacturing operations in the United States as well as internationally. The company operates across more than 100 countries and, through the broader CorDx Union ecosystem, claims a reach extending to over a billion users in 170+ countries. Its supply chain is vertically integrated, with strategic manufacturing footprints designed to support global distribution at scale. CorDx positions its work at the intersection of diagnostics, artificial intelligence, and data science, with active research and development underpinning its product portfolio. The company's stated focus is on expanding access to reliable, rapid diagnostics across both clinical and consumer health settings worldwide.

OpenEvidence is an AI-powered medical information platform built for healthcare professionals making clinical decisions at the point of care. Its core product functions as an AI copilot for physicians: clinicians submit clinical questions and receive evidence-based answers, synthesised from trusted medical literature and accompanied by references. The platform is available free to verified U.S. healthcare professionals. The platform has reached considerable scale within the U.S. medical community. More than 40% of U.S. physicians log in daily, and the platform has supported over 100 million AI-powered clinical consultations from doctors and frontline clinicians. OpenEvidence draws on partnerships with leading medical institutions and is designed for use across practice settings, from major hospital systems to rural clinics. The company operates at the intersection of several technical disciplines, including: Natural language processing applied to medical literature Clinical decision support and medical knowledge synthesis HIPAA-compliant health IT infrastructure Evidence-based AI for high-stakes clinical environments OpenEvidence is focused on the United States market and positions itself as a foundational layer for how physicians access and apply medical knowledge in practice.

Chai Discovery builds AI foundation models designed to predict and reprogram biochemical molecular interactions, with the goal of transforming drug discovery into an engineering discipline. The company's founders are researchers who co-invented protein language modeling and developed state-of-the-art protein folding algorithms. Chai Discovery is backed by OpenAI, Thrive Capital, and General Catalyst, and has a partnership with Eli Lilly. The company's core platform - anchored by its Chai-1 and Chai-2 models - predicts and redesigns interactions between biochemical molecules at atomic precision. Key capabilities include drug-like antibody design against challenging targets and the generation of functional GPCR agonists with minimal screening. The platform has reported a success rate of over 85% for computationally designed molecules meeting drug-like properties, a figure that contrasts with the traditional approach of screening millions or billions of protein sequences over years at a cost of billions of dollars. Chai Discovery's technical work spans several domains: Protein language modeling and folding algorithms Computational protein and antibody design GPCR agonist design Biopharma-focused machine learning Computational prediction of biochemical interactions The company focuses on targets traditionally considered undruggable, positioning its platform as a tool capable of addressing therapeutic challenges that conventional methods cannot efficiently reach.

AMTSOL delivers technology solutions for pharmaceutical and biotechnology manufacturers, specialising in the digitalization and automation of GMP-regulated manufacturing environments. The company's work spans the full stack of manufacturing systems - from Level 2 automation through to Level 5 cloud integration and data analytics - and covers the complete project lifecycle, from consultancy and implementation to validation and continuous improvement. Its core service areas include Manufacturing Execution Systems (MES), OT networking, automation, cloud integration, data analytics, and both Computerized System Validation (CSV) and Commissioning, Qualification, and Validation (CQV) services. AMTSOL operates as a vendor-independent, single-partner provider, taking full responsibility for consultancy, project support, and ongoing optimisation across each engagement. GMP compliance and data integrity are central to its delivery model. The company works with pharmaceutical and biotechnology organisations across Singapore, Europe, and the United States, with a focus on Pharma 4.0 adoption and digital transformation. Its stated operational priorities include helping regulated manufacturers increase speed to market and improve operating efficiency.